| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Clinical Research Centers |
Nemours Research Programs at the Nemours Children’s Clinic (N.M., V..H.), Jacksonville, Florida 32207; DuPont Hospital for Children (K.O.K.), Wilmington, Delaware 19803; and The Johns Hopkins University School of Hygiene and Public Health (K.O.O.), Baltimore, Maryland 21205-2179
Address all correspondence and requests for reprints to: Nelly Mauras, M.D., Nemours Children’s Clinic, 807 Nira Street, Jacksonville, Florida 32207. E-mail: nmauras{at}nemours.org
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Children with treatable forms of severe growth retardation presenting in puberty have the disadvantage of a limited time available for growth-promoting agents to work. Hence, GnRH analogs (GnRHa) have been commonly used to suppress puberty and delay epiphyseal fusion in this situation. Based on the knowledge gained from aromatase- and estrogen-deficient models, a better strategy to maximize height potential in very short males treated with recombinant human GH might be to suppress estrogen production while allowing complete virilization. This would offer potentially many advantages over GnRHa therapy.
Two recent developments now allow assessment of the effects of
selective estrogen suppression in males under controlled experimental
conditions. First is the availability of Arimidex (anastrozole,
AstraZeneca, Wilmington, DE); this is a novel, nonsteroidal aromatase
inhibitor [1,3-benzenediacetonitrile,
,,','-tetramethyl-5-(1H-1, 2, 4-triazol-1-ylmethyl)] that
blocks the conversion of 
4-androstenedione to
estrone and of testosterone to estradiol. It is metabolized mostly in
the liver (85%), with an elimination half-life of 50 h and a
terminal elimination half-life of 2 days. Plasma concentrations reach
steady state levels at about 7 days of once daily treatment. Extensive
data generated in both animals and humans indicate that this compound
has no other pharmacological effect in vivo (11, 12, 13); it is
presently an FDA-approved drug for the treatment of metastatic breast
cancer (14). Secondly, the availability of a highly sensitive estrogen
assay allows the measurement of circulating estradiol
(E2) concentrations at levels below those
detectable by conventional assays (15).
Hence, we designed these studies with the following specific questions. 1) What dose of anastrozole can be safely given in adolescent youngsters with minimal or no side-effects that maximally suppresses E2 concentrations? 2) Does anastrozole administration affect measures of whole body protein and bone calcium metabolism and GH production in males? To accomplish this, a group of young eugonadal males, in both late puberty and young adulthood, were recruited. Specific measures of intermediate metabolism were assessed before and after the administration of anastrozole.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
All studies were approved by the Nemours clinical research review committee and Wolfson Children’s Hospital institutional review board. The study drug was administered under the principal investigator’s (N.M.) own investigational new drug number assigned by the FDA.
Study 1 (question 1)
A group of 12 healthy young male volunteers (14–18 yr old; Tanner stage IV–V) was recruited after informed written consent was given. These subjects were given anastrozole orally at 2 different doses (0.5 or 1 mg) for 10 days, in random order, with 14 days of washout in between to allow approximately 7 half-lives of elimination of the drug. Blood was withdrawn in the early morning pre- and posttreatment for the measurement of serum testosterone, ultrasensitive E2, LH, FSH, dehydroepiandrosterone sulfate (DHEAS), and insulin-like growth factor I (IGF-I) concentrations. Liver function tests and blood counts were monitored also.
Study 2 (question 2)
Eight healthy male volunteers, aged 15–22 yr, were recruited after giving informed written consent. The subjects who were still growing were at least Tanner stage IV–V of genital development.
Experimental design
Before admission to the Wolfson Children’s Hospital clinical research center (CRC), subjects were encouraged to consume a weight maintenance diet for 3 days, consisting of approximately 35 Cal/kg and 1.5 g/kg protein·day. Dual emission x-ray absorptiometry (DEXA), using a tissue bar (Hologic 2000, Hologic, Inc., Waltham, MA) was used for assessment of bone mineral density and body composition; skinfold calipers and bioelectrical impedance analysis were also used . Isokinetic and isometric dynamometry of the anterior quadriceps was performed in our physical therapy department using a Biodex dynamometer (Biodex Corp., Shirley, NY). After a 10-min training session and 30 min of rest, maximum work and torque measurements for isometric and isokinetic tests were made. Isometric tests were performed with 5 contractions of 5 s each with the knee placed at 45° of flexion, with 10 s of rest between contractions. Isokinetic tests were performed for knee extension and flexion at 60°/s for 5 repetitions and at 180°/s for 21 repetitions as described previously (1).
The evening before admission to the CRC, after eating dinner at 1800 h, subjects were fasted, except for water ad libitum, until the completion of the studies at 1300 h the next day. The following morning (baseline study), the subjects were admitted to the CRC, and at 0600 h, two iv needles were placed in each antecubital vein; one was kept heated for arterialized blood sampling (16). At 0800 h (time zero) a primed, dose constant infusion of L-[1-13C]leucine (4.5 µmol/kg; 0.07 µmol/kg·min) was begun and was continued uninterrupted for the next 240 min. At time zero, 0.15 mg/kg 42Ca was also given as a slow iv push over 5 min. Frequent blood draws were performed as detailed below, and a urine collection was begun and continued for the next 28 h. Frequent breath samples were also obtained for determination of 13CO2 enrichment in expired breath. Using a mouthpiece, indirect calorimetry was performed three times during the 4 h of isotope infusion using a CPX max indirect calorimeter (Medical Graphics, St. Paul, MN) After the iv isotope infusions were completed at 1200 h, 0.3 mg/kg of a stable isotope of calcium (44Ca) was given orally mixed with juice (prepared at least 12 h before equilibration), and the patients were fed lunch. Subsequently, one iv line was discontinued, and subjects were free to move around until 1600 h, when a final blood sample was obtained for determination of Ca enrichments. Subjects were then sent home to complete the urine collection, and twice daily urine samples were obtained for determination of the Ca isotopic enrichments for the next 5 days.
After the baseline study and all urine collections were completed, patients were started on Arimidex at a dose of 1 mg given orally daily. Blood was withdrawn 1 and 4 weeks after the initiation of the treatment for determination of hormone concentrations and safety analysis (blood counts, urinalysis, and liver profiles). Ten weeks after the baseline study an identical study was carried out (D2).
Blood and breath samples
The isotopic enrichments of -ketoisocaproic acid
(13C labeled) were measured at -20, 160, 180,
200, 220, and 240 min. The Ca isotopic enrichments were measured at 0,
5, 10, 15, 20, 30, 40, 60, 120, 180, 240, and 480 min. Plasma IGF-I,
IGF-binding protein-3 (IGFBP-3), testosterone, free testosterone,
insulin, and glucose concentrations were measured three times during
the 240 min of tracer infusions. Serum GH concentrations were measured
at 10-min intervals for the 4 h of the studies. Serum lipids were
also measured while subjects were fasting on each study day. Breath
samples were obtained for the measurement of expired labeled
CO2 at -20, -10, -5, 160, 180, 200, and 220
min. A small aliquot of the urine collected during the 4-h morning
study was used for determination of the urea nitrogen
concentration.
Assays
Plasma enrichments of
[13C]-ketoisocaproic acid were determined at
the Nemours metabolic core laboratory by gas chromatography mass
spectrometry (17, 18) and
13CO2 by isotope ratio mass
spectrometry as described previously (19). Urinary Ca was determined by
flame atomic absorption spectrophotometry at the laboratory of Dr.
O’Brien. A dual filament thermal ionization quadrapole mass
spectrometer (Finnigan THQ, Finnigan MAT, Bremen, Germany) was
used to measure the Ca isotopic enrichments (20). Insulin was measured
by an immunoenzymatic method (Sanofi Pharmaceuticals, Inc., Chaska, MN), testosterone by a chemiluminescence assay
(Chiron Corp., East Walpole, MA), free testosterone by RIA
(Diagnostic Systems Laboratories, Inc., Webster, TX),
DHEAS by chemiluminescence (Diagnostic Products, Los
Angeles, CA), bone-specific alkaline phosphatase by an immunoassay
using a monoclonal antibody (Metra Biosystems, Mountain
View, CA), and osteocalcin by an immunoradiometric assay (Oris Group,
Gif-Sur-Yvette, France). IGF-1, IGFBP-1, IGFBP-2, and IGFBP-3 were
measured by immunoradiometric assays at the Mayo Clinic immunochemical
core laboratory (Rochester, MN). A sensitive chemiluminescence assay
was used to measure GH concentrations (21); LH and FSH were measured by
RIA, all at the University of Virginia General Clincial Research Center
core laboratory. A highly sensitive recombinant cell bioassay was used
to measure E2 concentrations with a sensitivity
of 0.2 pg/mL (0.73 pmol/L) (15). Urea nitrogen was measured using a
Kodak Ektakem urease method (Eastman Kodak Co., Rochester, NY).
Calculations
Estimates of rates of whole body protein turnover at steady
state were calculated using the reciprocal pool model as previously
described (17, 18). The fractional Ca absorption () was calculated
from the ratio of the cumulative excretion of the oral tracer
(44Ca) in urine divided by the cumulative
excretion of the iv tracer (42Ca) as previously
described (22, 23). True Ca absorption is determined by the formula
Va = Vi x , where Vi is the dietary Ca intake. Ca kinetic
analysis was performed by measuring the isotopic enrichments of the Ca
tracers in blood and urine over time using a multicompartmental model
and the simulation analysis and modeling program, SAAM, as previously
described (22, 24, 25). Substrate oxidation rates for protein, glucose,
and lipid and resting energy expenditure were calculated using the rate
of gas exchange (VO2 and
VCO2) from the indirect calorimetry as previously
described (26). Fat-free mass and percentage of fat mass were measured
using DEXA and the tissue bar as well as by the sum of skin folds as
described previously (27).
Data for changes in rates of leucine kinetics, body composition, and measures of muscle strength in the Arimidex-treated subjects were compared with the changes observed in eight GnRHa-treated males (aged, 18–25 yr) treated with the GnRHa Lupron for two doses of 7.5 mg, given 4 weeks apart. These subjects were studied identically as the present Arimidex-treated cohort, twice, 10 weeks apart, and some of their data have been reported previously (1, 28).
Isotopes and drugs
L-[1-13C]Leucine (99% enriched; Cambridge Isotopes, Andover, MA) and the 42Ca/44Ca ratio (93.5% and 96% enriched, respectively; Trace Sciences International, Richmond Hill, Canada) were determined to be sterile and pyrogen free and were mixed with 0.9% nonbacteriostatic saline. Arimidex (AstraZeneca Pharmaceuticals, Wilmington, DE) was bought commercially in 1-mg tablets.
Statistical analysis
Results are expressed as the mean ± SE. Paired Student’s t test was used to estimate differences between both study days. ANOVA was used to estimate the differences between Arimidex- vs. Lupron-treated subjects. Significance was established at P < 0.05.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Table 1
summarizes the changes in
circulating hormone concentrations after anastrozole administration.
Both doses were associated with comparable suppression of
E2 (
50%), with parallel increases in
testosterone and free testosterone concentrations without any change in
IGF-I (Fig. 1). Three subjects also
received 3 mg Arimidex in an identical paradigm, yet there was a
similar percent decline in E2 concentrations and
a reciprocal increase in testosterone concentrations as with the 0.5-
and 1-mg doses (data not shown). As all doses worked comparably in
suppressing estrogen concentrations, and the tablet is compounded as 1
mg, we chose to use 1 mg as the dose used for all subsequent
studies.
|
|
Growth factors, substrates, and hormones. Table 2 summarizes the changes in hormones,
growth factors, and glucose concentrations in the anastrozole-treated
subjects. The 50% suppression of plasma E2
observed in study 1 was sustained during the 10-week experiments, with
a reciprocal increase in circulating testosterone. This was accompanied
by a significant increase in circulating mean concentrations of
gonadotropins, measured at frequent intervals for 6 h. There was
no change in circulating sex hormone-binding globulin (SHBG) or DHEAS
concentrations. IGF-I concentrations decreased; however mean and peak
GH and IGFBP-3 concentrations remained invariant. Insulin and glucose
concentrations did not change, and bone growth factors also remained
invariant during the 10 weeks of anastrozole.
|
).
|
summarizes the measures of calcium
absorption ( and Va) as well as bone calcium deposition
(Vo+) and bone calcium resorption
(Vo-) during these experiments; they all
remained invariant. Urinary calcium excretion (Vu) did not change
significantly during these studies.
|
).
|
All subjects had blood counts, urinalysis, and liver profiles performed routinely during these studies, and low and high density lipoprotein concentrations were measured. There were no changes in any of these parameters during the 10-week experiments and no reported side-effects. The drug was well tolerated.
Comparison with Lupron
These results contrast sharply with those reported by us in a
similar group of young men (18–25 yr old) treated with the GnRHa
Lupron and studied also 10 weeks apart (1, 28). In those
subjects, GnRHa therapy significantly increased adiposity (percentage
of fat mass; P = 0.005), decreased rates of protein
synthesis (NOLD; P = 0.01), decreased lipid oxidation
(P = 0.05), decreased muscle strength
(P = 0.01), and markedly increased urinary calcium
losses (P = 0.003; Fig. 2). The E2
suppression in those subjects was also more severe, i.e.
3.90 ± 0.61 pg/mL on day 1 vs. 0.25 ± 0.07 on
day 2 (after Lupron).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
To answer the first question of this study, the use of different doses of anastrozole (0.5 and 1 mg) was associated with comparable suppression of E2 and reciprocal increases in testosterone and free testosterone concentrations without measurable changes in SHBG or IGF-I concentrations. We chose the 1-mg dose over the 0.5-mg dose because even though peripheral aromatase blockade appeared comparable to that with the 1-mg dose, it is possible that better aromatization blockade could be achieved at the tissue level with 1 mg. This in addition to the fact that the tablet is compounded as 1 mg made long term use of this drug easier. Even though this level of aromatase blockade achieved a 50% suppression of circulating E2 concentrations, we cannot a priori decide whether this suppression is any less than that observed in male patients with the aromatase gene mutations. This is because the estrogen assay used in the present studies is substantially more sensitive than that used in the previously described patients. In the subject reported by Carani et al. (9), for example, the E2 level was less than 10 pg/mL, whereas in our present study the assay sensitivity was 0.2 pg/mL; hence, whether this level of aromatase blockade is less than, the same as, or even more than that observed in patients with the mutations is unknown.
The biosynthesis of estrogens from C19 steroids is catalyzed by the aromatase cytochrome P450, a product of a single gene, cyp19. This enzyme is widely expressed in a multiplicity of tissues, including granulosa and luteal ovarian cells, Sertoli and Leydig cells of the testes, brain, adipocytes, liver, muscle, hair follicles, and, more recently, even bone (29, 30, 31, 32, 33, 34, 35). This enzyme converts androstenedione and testosterone to estrone and estradiol, respectively. After the administration of anastrozole, the 50% decrease in circulating E2 and the corresponding increase in testosterone concentrations observed during the short term experiments to answer question 1 were preserved, indicating a persistent and efficient block of aromatization after 10 weeks of continuous exposure.
There were no changes in SHBG or adrenal androgen concentrations with this relatively long-term period of administration. Abundant data both in vitro and in vivo clearly show that E2 administration is associated with an increase in circulating SHBG, whereas androgens decrease its concentration (36). However, this regulatory system is more complex than reflected by the changes in SHBG concentrations. It is now known that SHBG binds to a cell membrane receptor, which causes the activation of cAMP, and this interaction only happens when sex hormones bind to SHBG (37). This ligand-receptor interaction was obviously not measured in the present paradigm, and it is not known what effects, if any, the changes in the sex steroid milieu had on this. As in the present model, E2 concentrations decreased, with a reciprocal increase in testosterone; hence, the expected trend of a change in SHBG from the observed changes in sex steroid concentrations is negated. There was, however, a mild, but significant, increase in circulating gonadotropin levels. The latter supports the concept that E2 is a major regulator of gonadotropin feedback, even in the male (8, 38, 39).
During the 10-day experiments there was a modest, yet significant, increase in DHEAS concentrations after using either 0.5 or 1 mg anastrozole; however, this increase was not observed after 10 weeks of aromatase blockade. These are interesting, yet puzzling, observations. DHEAS is almost entirely adrenal in origin and, in addition to DHEA and androstenedione, is the major androgen produced by the adrenal glands. Under normal physiological circumstances DHEAS seems to contribute little to circulating testosterone or E2 concentrations, but could be converted to these steroids in certain tissues. It is conceivable that during the acute 10-day experiments DHEAS increased as a result of the aromatase blockade and the back-up of estrogen precursors. With more prolonged, persistent blockade of the tissue aromatase, it is possible that peripheral conversion of DHEAS contributed to the increase in testosterone concentrations. The latter consideration, however, is speculative and is not addressed directly in the present study.
Even though not apparent during the short, 10-day, dose-response experiments, prolonged administration of anastrozole resulted in a subtle, but significant, decline in IGF-I concentrations. This was, however, not associated with any detectable changes in circulating GH concentrations (as measured by frequent sampling) or plasma IGFBP-3 concentrations. This lack of effect on circulating GH concentrations was indeed somewhat unexpected, and it is possible that a larger number of subjects would have revealed a decrease in mean and peak GH concentrations, as six of eight subjects had a decrease in both of these measures. However, the relationship between estrogen and IGF-I may be complex and tissue specific, and other interpretations are plausible. Estrogen, for example, inhibits liver IGF-I production in hypophysectomized rats (40), and in postmenopausal women estrogen administration may attenuate the plasma IGF-I responses to exogenous GH (41), suggesting that in certain species estrogen may down-regulate hepatic GH receptors or impede tissue responses. It is possible that both androgens and estrogens participate in the regulation of GH production and that estrogen deficiency had an impact on the liver’s output of IGF-I in the male. Regardless, it is important to carefully monitor plasma IGF-I concentrations in any subjects who are actively growing and are being treated solely with anastrozole.
Measurements of whole body anabolism and intermediate metabolism remained invariant during 10 weeks of aromatase blockade. Rates of protein synthesis and degradation, as measured by leucine tracer studies, and rates of carbohydrate, protein, and lipid oxidation did not change significantly during treatment. Body composition (weight, fat-free mass, percent fat mass) and skeletal muscle strength were not affected by the suppression of E2 concentrations. These results differ significantly from the profound catabolic state observed in young males studied 10 weeks after GnRHa treatment with Lupron, in whom protein synthetic rates decreased, lipid oxidation rates decreased, adiposity increased, and muscle strength declined substantially after full suppression of the GnRH axis (1). These data suggest that suppression of estrogen concentrations at this level (50%) does not significantly affect large body protein pools and is congruent with observations in hypogonadal girls treated with estrogen reported previously (4).
The fact that we did not observe any detectable change in whole body protein kinetics or body composition despite the reciprocal increase in testosterone concentrations observed with anastrozole is also interesting. It is possible that this degree of increase in circulating androgens is not enough to see a change in protein kinetics and body composition with the metabolic tools of study used here. In the two models we used to show substantial anabolic effects of testosterone on whole body protein pools, the changes in testosterone concentrations were more profound than those observed here. In boys treated with testosterone (2) the testosterone concentration changed from 14 to 831 ng/dL, and in the young men rendered hypogonadal with Lupron (1) the decrease in testosterone concentrations was from 536 to 36 ng/dL, a 15- to 60-fold difference in concentrations, instead of the 1.5-fold difference observed here. Alternatively, the data could be interpreted to indicate that estrogen is necessary for the full anabolic effect of testosterone to be observed in the male. This requires further study.
The pivotal role of estrogens in the maintenance of skeletal mass is well characterized (42); hence, we were keenly interested in the effects of this level of suppression of E2 concentrations in males on measures of calcium fluxes and bone health. Even though DEXA scans obtained before and after treatment did not show any changes in mineralization (data not shown), 10-week experiments are not long enough to detect changes in bone mineral density. However, serum markers of bone formation, osteocalcin, and bone-specific alkaline phosphatase remained invariant during these studies. In addition, calcium kinetic analysis using stable tracers of calcium showed no significant changes in urinary calcium excretion or kinetic measures of bone calcium accretion and resorption. These findings again contrast with the marked changes in calcium kinetics observed after GnRHa therapy in a comparable group of young men studied identically, in whom profound gonadal steroid suppression was associated with increased urinary calcium loses, increased bone calcium contribution to those loses, and increased bone calcium resorption (28). One potential explanation for these findings is that the length of these experiments (10 weeks) was not enough to detect changes in bone calcium metabolism; however, the later explanation is unlikely, as marked changes in these same parameters were observed after GnRHa therapy in subjects studied for 10 weeks (28). Alternatively, it is possible that this degree of estrogen suppression at a 50% level may not have as profound an effect on bone as that observed after full estrogen receptor blockade (7) or complete gonadal steroid suppression (28). The reciprocal increase in testosterone concentrations may also serve a protective role of sorts in preventing bone loss, as androgens per se appear to have a critical effect as anabolic agents in bone (43).
Such a putative protective effect might not be operative, however, if the estrogen deficiency were complete and long term, such as that observed in patients with estrogen receptor and aromatase gene mutations (7, 8, 9). The fact that the few male subjects reported with either estrogen receptor or aromatase gene mutations all have had osteopenia clearly underscores the critical importance of estrogens in bone mineralization in the male; the data presented here do not contradict that. We can safely say, however, that within the narrow window of time of these studies (10 weeks), the same period of treatment with GnRHa in which we observed substantial negative effects in bone calcium metabolism in males of similar age (1, 28), we did not observe any deleterious effects in the exact same parameters as those used in those studies. Not only was the estrogen deficiency at the tissue level potentially more severe in the patients with aromatase and estrogen receptor mutations than that caused by anastrozole, but the length of the relative estrogen deficiency was longer by far in the patients than in the subjects reported here. It is hence prudent to carefully monitor bone mineralization and serum bone markers in subjects treated with any compounds that alter the sex steroidal milieu for a prolonged period. Continuous surveillance is clearly necessary.
GnRHa have been used extensively in short children in an attempt to delay epiphyseal fusion and increase ultimate height (44, 45, 46). Studies specifically looking at changes in body composition in this patient population are few, and the data are not consistent. Body mass index as the principal measure of adiposity was reported by Palmert et al. (47) in a group of 96 girls and 14 boys treated with GnRHa; it was found to be high in patients with precocious puberty even before treatment and was not worsened by therapy. This is a similar outcome as that observed by Heger et al. in 50 woman studied at final height (48). However, when better tools for the assessment of body composition (DEXA) are used prospectively and compared within patients with precocious puberty during treatment, fat mass and percent fat mass increased, whereas lean body mass decreased in a group of 34 children studied, of whom only 2 were boys (49). Our previously published data (1, 29) assess metabolic changes after GnRHa treatment and is perhaps the most extensive to date of any study; these data are congruent with those reported by Boot et al. regarding body composition. In addition to the lack of virilization caused by GnRHa, the detrimental effects on body composition; muscle strength; and protein, lipid, and calcium metabolism, make the use of these analogs unsuitable in the long term when the sole purpose of treatment is not precocious puberty per se, but to increase final height. The use of a potent selective aromatase blocker offers the advantage of continued virilization and maintenance of pubertal body composition while potentially delaying skeletal maturation. The latter is presently under investigation. Anastrozole treatment was well tolerated by all subjects. Glucose and insulin concentrations remained unchanged during these studies, as did plasma lipid concentrations, blood chemistries, and cell blood counts (data not shown).
In summary, this study of prolonged estrogen suppression for 10 weeks in young eugonadal subjects suggests that in the male estrogens do not contribute significantly to the changes in body composition and protein synthesis observed with changing androgen levels; estrogen is a main regulator of the gonadal-pituitary feedback for the gonadotropin axis; and this level of aromatase inhibition does not negatively impact markers of bone calcium metabolism, at least in the short term. In conclusion, 10 weeks of aromatase blockade in young males appears to be well tolerated and safe. Studies currently being conducted will provide valuable information on whether timed aromatase inhibition can be beneficial and safe in conditions of profound growth retardation in males. This strategy, if effective, may provide an advantage over the use of GnRHa to delay epiphyseal fusion.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
Received December 9, 1999.
Revised February 23, 2000.
Revised March 29, 2000.
Accepted April 13, 2000.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  B Lapauw, G T'Sjoen, A Mahmoud, J M Kaufman, and J B Ruige Short-term aromatase inhibition: effects on glucose metabolism and serum leptin levels in young and elderly men Eur. J. Endocrinol., March 1, 2009; 160(3): 397 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Loves, J. Ruinemans-Koerts, and H. de Boer Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism Eur. J. Endocrinol., May 1, 2008; 158(5): 741 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mauras, L. Gonzalez de Pijem, H. Y. Hsiang, P. Desrosiers, R. Rapaport, I. D. Schwartz, K. O. Klein, R. J. Singh, A. Miyamoto, and K. Bishop Anastrozole Increases Predicted Adult Height of Short Adolescent Males Treated with Growth Hormone: A Randomized, Placebo-Controlled, Multicenter Trial for One to Three Years J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 823 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Rochira, L. Zirilli, A. D Genazzani, A. Balestrieri, C. Aranda, B. Fabre, P. Antunez, C. Diazzi, C. Carani, and L. Maffei Hypothalamic-pituitary-gonadal axis in two men with aromatase deficiency: evidence that circulating estrogens are required at the hypothalamic level for the integrity of gonadotropin negative feedback. Eur. J. Endocrinol., October 1, 2006; 155(4): 513 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hero, C. Ankarberg-Lindgren, M.-R. Taskinen, and L. Dunkel Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition Eur. J. Endocrinol., September 1, 2006; 155(3): 453 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Giordano and G. N. Hortobagyi Leuprolide Acetate Plus Aromatase Inhibition for Male Breast Cancer J. Clin. Oncol., July 20, 2006; 24(21): e42 - e43. [Full Text] [PDF]
|
|
|
|
|
|
M. C M Bunck, A. W F T Toorians, P. Lips, and L. J G Gooren The effects of the aromatase inhibitor anastrozole on bone metabolism and cardiovascular risk indices in ovariectomized, androgen-treated female-to-male transsexuals. Eur. J. Endocrinol., April 1, 2006; 154(4): 569 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C K Hilleson-Gayne and J A Clapper Effects of decreased estradiol-17{beta} on the serum and anterior pituitary IGF-I system in pigs J. Endocrinol., December 1, 2005; 187(3): 369 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. T'Sjoen, V. A. Giagulli, H. Delva, P. Crabbe, D. De Bacquer, and J.-M. Kaufman Comparative Assessment in Young and Elderly Men of the Gonadotropin Response to Aromatase Inhibition J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5717 - 5722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Giordano A Review of the Diagnosis and Management of Male Breast Cancer Oncologist, August 1, 2005; 10(7): 471 - 479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Zhou, B. Shah, K. Prasad, and R. David Letrozole Significantly Improves Growth Potential in a Pubertal Boy With Growth Hormone Deficiency Pediatrics, February 1, 2005; 115(2): e245 - e248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Cherrier, A. M. Matsumoto, J. K. Amory, S. Ahmed, W. Bremner, E. R. Peskind, M. A. Raskind, M. Johnson, and S. Craft The role of aromatization in testosterone supplementation: Effects on cognition in older men Neurology, January 25, 2005; 64(2): 290 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Coutant, F. B. de Casson, S. Rouleau, O. Douay, E. Mathieu, F. Gatelais, N. Bouhours-Nouet, C. Voinot, M. Audran, and J. M. Limal Divergent Effect of Endogenous and Exogenous Sex Steroids on the Insulin-Like Growth Factor I Response to Growth Hormone in Short Normal Adolescents J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6185 - 6192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. V. Plourde, E. O. Reiter, H.-C. Jou, P. E. Desrochers, S. D. Rubin, B. B. Bercu, F. B. Diamond Jr., and P. F. Backeljauw Safety and Efficacy of Anastrozole for the Treatment of Pubertal Gynecomastia: A Randomized, Double-Blind, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4428 - 4433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Vanderschueren, L. Vandenput, S. Boonen, M. K. Lindberg, R. Bouillon, and C. Ohlsson Androgens and Bone Endocr. Rev., June 1, 2004; 25(3): 389 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Z. Leder, J. L. Rohrer, S. D. Rubin, J. Gallo, and C. Longcope Effects of Aromatase Inhibition in Elderly Men with Low or Borderline-Low Serum Testosterone Levels J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1174 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Maffei, Y. Murata, V. Rochira, G. Tubert, C. Aranda, M. Vazquez, C. D. Clyne, S. Davis, E. R. Simpson, and C. Carani Dysmetabolic Syndrome in a Man with a Novel Mutation of the Aromatase Gene: Effects of Testosterone, Alendronate, and Estradiol Treatment J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 61 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mauras, J. Lima, D. Patel, A. Rini, E. di Salle, A. Kwok, and B. Lippe Pharmacokinetics and Dose Finding of a Potent Aromatase Inhibitor, Aromasin (Exemestane), in Young Males J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5951 - 5956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. O. Klein, M. Janfaza, J. A. Wong, and R. J. Chang Estrogen Bioactivity in Fo-Ti and Other Herbs Used for Their Estrogen-Like Effects as Determined by a Recombinant Cell Bioassay J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4077 - 4079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Herrmann, B. Saller, O. E. Janssen, P. Gocke, A. Bockisch, H. Sperling, K. Mann, and M. Broecker Impact of Estrogen Replacement Therapy in a Male with Congenital Aromatase Deficiency Caused by a Novel Mutation in the CYP19 Gene J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5476 - 5484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Gillam, S. Middler, D. J. Freed, and M. E. Molitch The Novel Use of Very High Doses of Cabergoline and a Combination of Testosterone and an Aromatase Inhibitor in the Treatment of a Giant Prolactinoma J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4447 - 4451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Rochira, A. Balestrieri, M. Faustini-Fustini, S. Borgato, P. Beck-Peccoz, and C. Carani Pituitary Function in a Man with Congenital Aromatase Deficiency: Effect of Different Doses of Transdermal E2 on Basal and Stimulated Pituitary Hormones J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2857 - 2862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Saad, B. S. Keenan, K. Danadian, V. D. Lewy, and S. A. Arslanian Dihydrotestosterone Treatment in Adolescents with Delayed Puberty: Does it Explain Insulin Resistance of Puberty? J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4881 - 4886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wickman and L. Dunkel Inhibition of P450 Aromatase Enhances Gonadotropin Secretion in Early and Midpubertal Boys: Evidence for a Pituitary Site of Action of Endogenous E J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4887 - 4894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Kaplowitz If Gonadotropin-Releasing Hormone Plus Growth Hormone (GH) Really Improves Growth Outcomes in Short Non-GH-Deficient Children, Then What? J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 2965 - 2968. [Full Text] [PDF]
|
|
|
|
|
|
L. O'Donnell, K. M. Robertson, M. E. Jones, and E. R. Simpson Estrogen and Spermatogenesis Endocr. Rev., June 1, 2001; 22(3): 289 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Schnorr, M. J. Bray, and J. D. Veldhuis Aromatization Mediates Testosterone's Short-Term Feedback Restraint of 24-Hour Endogenously Driven and Acute Exogenous Gonadotropin-Releasing Hormone-Stimulated Luteinizing Hormone and Follicle-Stimulating Hormone Secretion in Young Men J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2600 - 2606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Taxel, D. G. Kennedy, P. M. Fall, A. K. Willard, J. M. Clive, and L. G. Raisz The Effect of Aromatase Inhibition on Sex Steroids, Gonadotropins, and Markers of Bone Turnover in Older Men J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2869 - 2874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Rochira Aromatase Inhibitors in Pubertal Boys: Clinical Implications J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1836 - 1837. [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
) and
after 10 days of oral anastrozole at 0.5 and 1 mg.
; n = 6) in healthy boys and young men
for whole body protein synthesis rates (NOLD), percentage of fat mass
measured by DEXA, and urinary calcium excretion (Vu) measured by
calcium tracers. Data are expressed as the absolute change from
baseline. Comparisons were made using ANOVA between the groups.